Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Birmingham Vasculitis Activity Scores (BVAS) were used to identify disease manifestations. Key efficacy outcomes included remission at week 26, sustained remission at week 52, relapse rates, the ...